{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:11:27Z","timestamp":1790644287204,"version":"4.1.0"},"reference-count":159,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871281"],"award-info":[{"award-number":["31871281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2020XGKY12"],"award-info":[{"award-number":["2020XGKY12"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine","award":["31871281"],"award-info":[{"award-number":["31871281"]}]},{"name":"Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine","award":["2020XGKY12"],"award-info":[{"award-number":["2020XGKY12"]}]},{"name":"Shanghai Municipal Health Commission","award":["31871281"],"award-info":[{"award-number":["31871281"]}]},{"name":"Shanghai Municipal Health Commission","award":["2020XGKY12"],"award-info":[{"award-number":["2020XGKY12"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>In recent years, the FDA has approved numerous anti-cancer drugs that are mutation-based for clinical use. These drugs have improved the precision of treatment and reduced adverse effects and side effects. Personalized therapy is a prominent and hot topic of current medicine and also represents the future direction of development. With the continuous advancements in gene sequencing and high-throughput screening, research and development strategies for personalized clinical drugs have developed rapidly. This review elaborates the recent personalized treatment strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, and computation-aided drug design. These technologies rely on the molecular classification of diseases, the global signaling network within organisms, and new models for all targets, which significantly support the development of personalized medicine. Meanwhile, we summarize chemical drugs, such as lorlatinib, osimertinib, and other natural products, that deliver personalized therapeutic effects based on genetic mutations. This review also highlights potential challenges in interpreting genetic mutations and combining drugs, while providing new ideas for the development of personalized medicine and pharmacogenomics in cancer study.<\/jats:p>","DOI":"10.3390\/genes15040468","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T10:11:55Z","timestamp":1712571115000},"page":"468","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products"],"prefix":"10.3390","volume":"15","author":[{"given":"Yalan","family":"Zhou","sequence":"first","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyin","family":"Cai","sequence":"additional","affiliation":[{"name":"Shanghai R&D Centre for Standardization of Chinese Medicines, Shanghai 202103, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-996X","authenticated-orcid":false,"given":"Qingzhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Su, M., Zhang, Z., Zhou, L., Han, C., Huang, C., and Nice, E.C. (2021). Proteomics, personalized medicine and cancer. Cancers, 13.","DOI":"10.3390\/cancers13112512"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/wsbm.1198","article-title":"Promise of personalized omics to precision medicine","volume":"5","author":"Chen","year":"2013","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/gt.2017.77","article-title":"Human genomics projects and precision medicine","volume":"24","author":"Aguado","year":"2017","journal-title":"Gene Ther."},{"key":"ref_4","first-page":"548","article-title":"Personalized medicine","volume":"4","author":"Jain","year":"2002","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00428-022-03267-x","article-title":"Updates on breast biomarkers","volume":"480","author":"Najjar","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cecchin, E., and Stocco, G. (2020). Pharmacogenomics and Personalized Medicine. Genes, 11.","DOI":"10.3390\/genes11060679"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fphar.2020.00969","article-title":"Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions","volume":"11","author":"Chang","year":"2020","journal-title":"Front. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2677","DOI":"10.1002\/hup.2677","article-title":"Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers","volume":"33","author":"Zastrozhin","year":"2018","journal-title":"Hum. Psychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0361-090X(02)00126-5","article-title":"Pharmacogenomics in cancer drug discovery and development: Inhibitors of the Hsp90 molecular chaperone","volume":"26","author":"Workman","year":"2002","journal-title":"Cancer Detect. Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal. Transduct. Target."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/07388551.2014.959891","article-title":"Development and use of molecular markers: Past and present","volume":"36","author":"Grover","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yu, T.W., Lane, H.Y., and Lin, C.H. (2021). Novel Therapeutic Approaches for Alzheimer\u2019s Disease: An Updated Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158208"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","article-title":"FDA Approval Summary: Ramucirumab for Gastric Cancer","volume":"21","author":"Casak","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/jphp.12384","article-title":"New forms of old drugs: Improving without changing","volume":"67","author":"Domingos","year":"2015","journal-title":"J. Pharm. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2174\/1389450115666140714121514","article-title":"New use for old drugs? Prospective targets of chloroquines in cancer therapy","volume":"15","author":"Vlahopoulos","year":"2014","journal-title":"Curr. Drug. Targets"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/014107688708000705","article-title":"New drugs for mental diseases? New diseases for old drugs?","volume":"80","author":"Joyce","year":"1987","journal-title":"J. R. Soc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.2174\/0929867326666190628163633","article-title":"Old Antiprotozoal Drugs: Are They Still Viable Options for Parasitic Infections or New Options for Other Diseases?","volume":"27","author":"Palos","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10557-018-6785-y","article-title":"Old Drugs for New Indications in Cardiovascular Medicine","volume":"32","author":"Arbel","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1111\/bph.12624","article-title":"Something old, something new and something very old: Drugs for treating type 2 diabetes","volume":"171","author":"Kaiser","year":"2014","journal-title":"Br. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2018.12.003","article-title":"New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology","volume":"73","author":"Janiaud","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/1389201018666170224105600","article-title":"Clinical Applications of Personalized Medicine: A New Paradigm and Challenge","volume":"18","author":"Cipolloni","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.ctarc.2021.100492","article-title":"Oncology drug-companion diagnostic combinations","volume":"29","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40504-016-0041-7","article-title":"Continental philosophical perspectives on life sciences and emerging technologies","volume":"12","author":"Zwart","year":"2016","journal-title":"Life Sci. Soc. Policy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-021-02910-6","article-title":"Translational precision medicine: An industry perspective","volume":"19","author":"Hartl","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_29","first-page":"5048","article-title":"Research and development of new traditional Chinese medicine drugs for certain syndromes based on \u201ctheoretical innovation\u201d","volume":"45","author":"Lian","year":"2020","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1007\/s00018-015-1934-y","article-title":"Whole transcriptome analysis with sequencing: Methods, challenges and potential solutions","volume":"72","author":"Jiang","year":"2015","journal-title":"Cell Mol. Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41576-020-0210-7","article-title":"Pan-genomics in the human genome era","volume":"21","author":"Sherman","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/acs.jproteome.0c00409","article-title":"Proteome-Scale Analysis of Protein S-Acylation Comes of Age","volume":"20","author":"Wang","year":"2021","journal-title":"J. Proteome Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.18097\/pbmc20226805321","article-title":"Metabolome profiling in the study of aging processes","volume":"68","author":"Balashova","year":"2022","journal-title":"Biomed. Khim"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"806842","DOI":"10.3389\/fgene.2022.806842","article-title":"MoGCN: A Multi-Omics Integration Method Based on Graph Convolutional Network for Cancer Subtype Analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.semnuclmed.2020.02.005","article-title":"The Future of Cardiac Molecular Imaging","volume":"50","author":"Farber","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apcsb.2019.11.008","article-title":"Latest trends in structure based drug design with protein targets","volume":"121","author":"Bagchi","year":"2020","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00894-006-0141-z","article-title":"Bayesian data mining of protein domains gives an efficient predictive algorithm and new insight","volume":"13","author":"Joshi","year":"2007","journal-title":"J. Mol. Model."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1308\/147870804290","article-title":"Artificial intelligence in medicine","volume":"86","author":"Ramesh","year":"2004","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101895","DOI":"10.1016\/j.mex.2022.101895","article-title":"How-to conduct a systematic literature review: A quick guide for computer science research","volume":"9","author":"Ochoa","year":"2022","journal-title":"MethodsX"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jormas.2022.01.010","article-title":"Artificial intelligence for oral and maxillo-facial surgery: A narrative review","volume":"123","author":"Rasteau","year":"2022","journal-title":"J. Stomatol. Oral. Maxillofac. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wang, A., Xiu, X., Liu, S., Qian, Q., and Wu, S. (2022). Characteristics of Artificial Intelligence Clinical Trials in the Field of Healthcare: A Cross-Sectional Study on ClinicalTrials.gov. Int. J. Env. Res. Public. Health, 19.","DOI":"10.3390\/ijerph192013691"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/03091902.2020.1769758","article-title":"Big data analytics in medical engineering and healthcare: Methods, advances and challenges","volume":"44","author":"Wang","year":"2020","journal-title":"J. Med. Eng. Technol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/138920012802138589","article-title":"De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes","volume":"13","author":"Dallas","year":"2012","journal-title":"Curr. Drug. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104151","DOI":"10.1016\/j.compbiomed.2020.104151","article-title":"Machine learning model for predicting malaria using clinical information","volume":"129","author":"Lee","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13555-020-00372-0","article-title":"Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations","volume":"10","author":"Chan","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cac2.12012","article-title":"Emerging role of deep learning-based artificial intelligence in tumor pathology","volume":"40","author":"Jiang","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e229960","DOI":"10.1001\/jamanetworkopen.2022.9960","article-title":"Artificial Intelligence for Screening of Multiple Retinal and Optic Nerve Diseases","volume":"5","author":"Dong","year":"2022","journal-title":"JAMA Netw. Open."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41551-018-0305-z","article-title":"Artificial intelligence in healthcare","volume":"2","author":"Yu","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1107689","DOI":"10.3389\/fcell.2022.1107689","article-title":"Advances in artificial intelligence applications for ocular surface diseases diagnosis","volume":"10","author":"Ji","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_50","first-page":"647","article-title":"Application and development of voice analysis and endoscopic technology combined with artificial intelligence in the diagnosis and treatment of throat disease","volume":"36","author":"Song","year":"2022","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tig.2020.01.009","article-title":"A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine","volume":"36","author":"Ye","year":"2020","journal-title":"Trends Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/cpbi.86","article-title":"Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis","volume":"68","author":"Chong","year":"2019","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","article-title":"Targeting Fyn Kinase in Alzheimer\u2019s Disease","volume":"83","author":"Nygaard","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2020.11.002","article-title":"Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer\u2019s Disease","volume":"109","author":"Wang","year":"2021","journal-title":"Neuron"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1600-0447.2009.01434.x","article-title":"Do the old psychostimulant drugs have a role in managing treatment-resistant depression?","volume":"121","author":"Parker","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_56","first-page":"414","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"McDonagh","year":"2012","journal-title":"Clin. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cac2.12224","article-title":"Tumor organoids: Synergistic applications, current challenges, and future prospects in cancer therapy","volume":"41","author":"Qu","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Park, M., Kim, D., Moon, K., and Park, T. (2020). Integrative Analysis of Multi-Omics Data Based on Blockwise Sparse Principal Components. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218202"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-022-01526-8","article-title":"Proteomics technologies for cancer liquid biopsies","volume":"21","author":"Ding","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12931-022-02233-0","article-title":"Personalized medicine using omics approaches in acute respiratory distress syndrome to identify biological phenotypes","volume":"23","author":"Battaglini","year":"2022","journal-title":"Respir. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1021\/acs.accounts.1c00065","article-title":"Reimagining Druggability Using Chemoproteomic Platforms","volume":"54","author":"Spradlin","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14789450.2021.1914595","article-title":"The role of proteomics in defining autoimmunity","volume":"18","author":"Kanduc","year":"2021","journal-title":"Expert. Rev. Proteom."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.cell.2022.03.040","article-title":"In situ identification of cellular drug targets in mammalian tissue","volume":"185","author":"Pang","year":"2022","journal-title":"Cell."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/1389450116666150907104855","article-title":"CADD Modeling of Multi-Target Drugs Against Alzheimer\u2019s Disease","volume":"18","author":"Ambure","year":"2017","journal-title":"Curr. Drug. Targets"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"21984","DOI":"10.1073\/pnas.0910040106","article-title":"Target identification using drug affinity responsive target stability (DARTS)","volume":"106","author":"Lomenick","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.trecan.2021.10.002","article-title":"Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms","volume":"8","author":"Li","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/10409238.2021.1937928","article-title":"Modular optimization in metabolic engineering","volume":"56","author":"Wong","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0928-0987(01)00111-7","article-title":"Computer-assisted drug development (CADD): An emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments","volume":"13","author":"Gomeni","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cbpa.2009.03.021","article-title":"The therapeutic potential of phosphatase inhibitors","volume":"13","author":"Vintonyak","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1570159X18666191230120053","article-title":"Potential Therapeutic Approaches to Alzheimer\u2019s Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools","volume":"18","author":"Avram","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mnfr.200500273","article-title":"Introduction to bioinformatics","volume":"50","author":"Akalin","year":"2006","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_73","first-page":"14.1.1","article-title":"Introduction to cheminformatics","volume":"14","author":"Wishart","year":"2007","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1021\/acs.jcim.7b00316","article-title":"Predicted Biological Activity of Purchasable Chemical Space","volume":"58","author":"Irwin","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.csbj.2020.02.001","article-title":"Applications of water molecules for analysis of macromolecule properties","volume":"18","author":"Bagrowska","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1111\/bph.15657","article-title":"Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments","volume":"178","author":"Zobdeh","year":"2021","journal-title":"Br. J. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Pinzi, L., and Rastelli, G. (2019). Molecular Docking: Shifting Paradigms in Drug Discovery. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184331"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2174\/1389557520666200526183353","article-title":"Performance Evaluation of Docking Programs- Glide, GOLD, AutoDock & SurflexDock, Using Free Energy Perturbation Reference Data: A Case Study of Fructose-1, 6-bisphosphatase-AMP Analogs","volume":"20","author":"Reddy","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-4939-9869-2_17","article-title":"Molecular Dynamics Simulation of Proteins","volume":"2073","author":"Collier","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4939-9608-7_9","article-title":"Protein-Ligand Binding Free Energy Calculations with FEP","volume":"2022","author":"Wang","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11030-021-10217-3","article-title":"Artificial intelligence to deep learning: Machine intelligence approach for drug discovery","volume":"25","author":"Gupta","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Hessler, G., and Baringhaus, K.H. (2018). Artificial Intelligence in Drug Design. Molecules, 23.","DOI":"10.3390\/molecules23102520"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cmdc.201100510","article-title":"Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor\u20055 (mGlu\u2085): From an artificial neural network virtual screen to an in vivo tool compound","volume":"7","author":"Mueller","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/chan.4999","article-title":"Ligand-based virtual screening to identify new T-type calcium channel blockers","volume":"1","author":"Ijjaali","year":"2007","journal-title":"Channels"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Dembic, Z. (2020). Antitumor Drugs and Their Targets. Molecules, 25.","DOI":"10.3390\/molecules25235776"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000511107","article-title":"Personalized Immuno-Oncology","volume":"30","author":"Jain","year":"2021","journal-title":"Med. Princ. Pr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: Precision Medicine Takes on Drug Resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs Crizotinib for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.2217\/fon-2021-0608","article-title":"Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)","volume":"17","author":"Popat","year":"2021","journal-title":"Future Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1038\/s41598-021-86021-8","article-title":"Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines","volume":"11","author":"Taniguchi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2217\/fon-2022-0184","article-title":"Lorlatinib as a treatment for ALK-positive lung cancer","volume":"18","author":"Baba","year":"2022","journal-title":"Future Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1002\/ijc.30691","article-title":"Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis","volume":"140","author":"Yang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/apm-20-2140","article-title":"Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer","volume":"10","author":"Cheng","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_108","first-page":"16","article-title":"Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen Trometamol and Evaluation of In Vitro Characteristic Properties","volume":"15","year":"2018","journal-title":"Turk. J. Pharm. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13045-020-01009-7","article-title":"Abnormally activated OPN\/integrin \u03b1V\u03b23\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer","volume":"13","author":"Fu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1078155220931926","article-title":"Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings","volume":"26","author":"Harvey","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2013.09.007","article-title":"Pharmacokinetics","volume":"87","author":"Fan","year":"2014","journal-title":"Biochem. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics--drug disposition, drug targets, and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0091270010374472","article-title":"Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast","volume":"51","author":"Mougey","year":"2011","journal-title":"J. Clin. Pharm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd4510","article-title":"The re-emergence of natural products for drug discovery in the genomics era","volume":"14","author":"Harvey","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.phrs.2018.01.015","article-title":"Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms","volume":"130","author":"Xu","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchem.2479","article-title":"Counting on natural products for drug design","volume":"8","author":"Rodrigues","year":"2016","journal-title":"Nat. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.molcel.2020.01.009","article-title":"Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss","volume":"77","author":"Liu","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1161\/CIRCULATIONAHA.120.048378","article-title":"Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human","volume":"142","author":"Pan","year":"2020","journal-title":"Circulation"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41388-019-1079-9","article-title":"Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage","volume":"39","author":"Warren","year":"2020","journal-title":"Oncogene"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","article-title":"Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem","volume":"26","author":"Cuevas","year":"2009","journal-title":"Nat. Prod. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/cam4.1403","article-title":"Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: An updated analysis of the EORTC 62091 trial","volume":"7","author":"Italiano","year":"2018","journal-title":"Cancer Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2016.09.009","article-title":"Trabectedin as a chemotherapy option for patients with BRCA deficiency","volume":"50","author":"Monk","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","article-title":"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage","volume":"95","author":"Yoshida","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_131","unstructured":"Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (1993). GeneReviews(\u00ae), University of Washington. University of Washington, Seattle Copyright \u00a9 1993\u20132023."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study","volume":"391","author":"Hilling","year":"2018","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"26854","DOI":"10.1002\/pbc.26854","article-title":"CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer","volume":"65","author":"Skiles","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2169\/internalmedicine.46.0203","article-title":"Giant cell tumor of the rib","volume":"46","author":"Maki","year":"2007","journal-title":"Intern. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Uittenboogaard, A., Neutel, C.L.G., Ket, J.C.F., Njuguna, F., Huitema, A.D.R., Kaspers, G.J.L., and van de Velde, M.E. (2022). Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14030612"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Losuwannarak, N., Maiuthed, A., Kitkumthorn, N., Leelahavanichkul, A., Roytrakul, S., and Chanvorachote, P. (2019). Gigantol Targets Cancer Stem Cells and Destabilizes Tumors via the Suppression of the PI3K\/AKT and JAK\/STAT Pathways in Ectopic Lung Cancer Xenografts. Cancers, 11.","DOI":"10.3390\/cancers11122032"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"836564","DOI":"10.1155\/2015\/836564","article-title":"Gigantol Suppresses Cancer Stem Cell-Like Phenotypes in Lung Cancer Cells","volume":"2015","author":"Bhummaphan","year":"2015","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"781","DOI":"10.21873\/cgp.20232","article-title":"Gigantol Targets MYC for Ubiquitin-proteasomal Degradation and Suppresses Lung Cancer Cell Growth","volume":"17","author":"Losuwannarak","year":"2020","journal-title":"Cancer Genom. Proteom."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"McCorkle, J.R., Gorski, J.W., Liu, J., Riggs, M.B., McDowell, A.B., Lin, N., Wang, C., Ueland, F.R., and Kolesar, J.M. (2021). Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0254205"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"759146","DOI":"10.3389\/fphar.2021.759146","article-title":"Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer","volume":"12","author":"Heersche","year":"2021","journal-title":"Front. Pharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"152932","DOI":"10.1016\/j.phymed.2019.152932","article-title":"Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression","volume":"62","author":"Bhummaphan","year":"2019","journal-title":"Phytomedicine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41576-020-0265-5","article-title":"Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics","volume":"22","author":"Nam","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13353-011-0057-x","article-title":"Sequencing technologies and genome sequencing","volume":"52","author":"Pareek","year":"2011","journal-title":"J. Appl. Genet."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.molcel.2015.05.004","article-title":"High-throughput sequencing technologies","volume":"58","author":"Reuter","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0071-8","article-title":"Single-cell RNA sequencing technologies and bioinformatics pipelines","volume":"50","author":"Hwang","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.trsl.2019.08.005","article-title":"siRNA therapeutics for breast cancer: Recent efforts in targeting metastasis, drug resistance, and immune evasion","volume":"214","author":"Ngamcherdtrakul","year":"2019","journal-title":"Transl. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/1061186X.2017.1419363","article-title":"Translation of combination nanodrugs into nanomedicines: Lessons learned and future outlook","volume":"26","author":"Mu","year":"2018","journal-title":"J. Drug. Target."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Cilento, M.E., Ong, Y.T., Tedbury, P.R., and Sarafianos, S.G. (2022). Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. Viruses, 14.","DOI":"10.3390\/v14061202"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Liang, Z., He, Y., and Hu, X. (2022). Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810617"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"9s","DOI":"10.2967\/jnumed.115.157834","article-title":"Clinical Diagnosis and Management of Breast Cancer","volume":"57","author":"McDonald","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","article-title":"Enabling Technologies for Personalized and Precision Medicine","volume":"38","author":"Ho","year":"2020","journal-title":"Trends Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/apm.12934","article-title":"Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases","volume":"127","author":"Litman","year":"2019","journal-title":"Apmis"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2016.12.023","article-title":"Safe approaches for camptothecin delivery: Structural analogues and nanomedicines","volume":"247","author":"Botella","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Thomford, N.E., Senthebane, D.A., Rowe, A., Munro, D., Seele, P., Maroyi, A., and Dzobo, K. (2018). Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061578"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/4\/468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:24:40Z","timestamp":1760106280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/4\/468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":159,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["genes15040468"],"URL":"https:\/\/doi.org\/10.3390\/genes15040468","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}